Navigation Links
CEL-SCI Corporation Reports 2009 Second Fiscal Quarter Financial Results

VIENNA, Va., May 15 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE AMEX: CVM) announced today financial results for its second fiscal quarter for the period ended March 31, 2009.

Financial results:

  • Net loss for three months ended March 31, 2009 was $1,894,753, a decline of 41% compared to a net loss of $3,210,294 during the same quarter in 2008.
  • The net loss per common share for the quarter ended March 31, 2009 was $0.02 compared to $0.03 for the same quarter in 2008.
  • During the six-month period ended March 31, 2009 the Company used cash in operations totaling $57,092 while during the six-month period ended March 31, 2008 it used $10,728,203. For the six months ended March 31, 2009 and 2008, cash provided by financing activities totaled $1,218,734 and $180,443, respectively.

Some of the recent highlights include:

  • Licensing Agreement for Multikine. The Company entered into an agreement with Byron Biopharma ("Byron") under which CEL-SCI has granted Byron an exclusive license to market and distribute the Company's cancer drug Multikine(R) in the Republic of South Africa. Byron will also be responsible for registering the product in the country. CEL-SCI already has existing licensing agreements for Multikine with Teva Pharmaceuticals and Orient Europharma.
  • Launch of cold 4 degrees Celsius Aseptic Filling manufacturing process. The Company launched a new manufacturing process that could allow drugs developed using stem cells and other biological products to maintain their potency and thereby potentially also their shelf life. The availability of this new process developed by CEL-SCI may also significantly accelerate the time to market by eliminating complicated and time consuming validation studies and tests required when these products are filled at room temperature. The use of a cold 4 degrees Celsius fill, as opposed to the normal room temperature fill, significantly increases the probability of maintaining drug activity, potency and thus potentially extending the shelf life of new biological and stem cell produced products.
  • Promising preclinical studies supporting the Company's proprietary L.E.A.P.S.(TM) (Ligand Epitope Antigen Presentation System) vaccine technology. The studies suggest that L.E.A.P.S. could potentially induce protection against illnesses such as swine influenza. In pre-clinical studies using mouse models, several different L.E.A.P.S. conjugates focused on different diseases induced protection and disease improvement. In addition, it was recently presented that the L.E.A.P.S. vaccines work on human cells and that the L.E.A.P.S. vaccines are able to induce cellular responses without excessive amounts of pro-inflammatory cytokines. In the case of prior pandemic influenza, such as the "Spanish Influenza" and more recently in avian flu, patients with stronger immune systems had a greater chance of dying because their immune response was too strong (too many pro-inflammatory cytokines). A L.E.A.P.S. vaccine may be able to work around that problem. While normally cytokines may play a key role in preventing and treating swine flu, in some cases excessive cytokine amounts may exacerbate disease as it appears that, unlike the normal flu which affects the very young and very old most severely, swine flu may be more like the avian flu which hits people in their prime more severely.

CEL-SCI Corporation develops immune-based cancer and infectious disease therapies. Its primary product candidate is Multikine, a next-generation, comprehensive immunotherapy that targets newly diagnosed head and neck cancer. Multikine is cleared by the FDA and the Canadian regulators for a global Phase III clinical trial in newly diagnosed head and neck cancer. In a Phase II long term follow-up trial with Multikine, a 33% improvement in overall survival was observed.

The Company has operations in Vienna, Virginia and Baltimore, Maryland. CEL-SCI's other products, which are currently in pre-clinical stage, have shown protection against a number of diseases in animal tests and are being/have been tested against diseases associated with bio-defense, rheumatoid arthritis, and pandemic flu.

                               CEL-SCI CORPORATION

                                                        Three Months Ended
                                                             March 31,
                                                      2009               2008
       Rent income                                 $19,643                 $-
                      Total Revenue                 19,643                  -
       Research and development, excluding
        depreciation of $101,108 and $97,035
        included below                           1,025,236          1,037,063
       Depreciation and amortization               122,598             79,215
       General and administrative                1,014,399            968,820

                        Total Expenses           2,162,233          2,085,098

     LOSS FROM OPERATIONS                       (2,142,590)        (2,085,098)

     GAIN (LOSS) ON DERIVATIVE INSTRUMENTS         264,554         (1,160,937)

     INTEREST INCOME                                68,160            157,256

     INTEREST EXPENSE                              (84,877)          (121,515)

     NET LOSS BEFORE INCOME TAXES               (1,894,753)        (3,210,294)

     INCOME TAX PROVISION                                -                  -

     NET LOSS                                   (1,894,753)        (3,210,294)

     DIVIDENDS                                           -           (424,815)

     NET LOSS AVAILABLE TO COMMON SHAREHOLDERS $(1,894,753)       $(3,635,109)

     NET LOSS PER COMMON SHARE (BASIC)              $(0.02)            $(0.03)

     NET LOSS PER COMMON SHARE (DILUTED)            $(0.02)            $(0.03)

      OUTSTANDING                              124,701,667        116,312,378

                               CEL-SCI CORPORATION

                                                        Six Months Ended
                                                             March 31,
                                                      2009               2008
       Rent income                                 $19,643             $1,530
                        Total Revenue               19,643              1,530
       Research and development, excluding
        depreciation of $165,631 and $97,856
        included below                           2,213,462          2,066,029
       Depreciation and amortization               208,542            133,468
       General and administrative                2,069,525          2,754,569

                        Total Expenses           4,491,529          4,954,066

     LOSS FROM OPERATIONS                       (4,471,886)        (4,952,536)

     GAIN (LOSS) ON DERIVATIVE INSTRUMENTS         656,243           (170,949)

     INTEREST INCOME                               139,397            335,987

     INTEREST EXPENSE                             (169,493)          (265,531)

     NET LOSS BEFORE INCOME TAXES               (3,845,739)        (5,053,029)

     INCOME TAX PROVISION                                -                  -

     NET LOSS                                  $(3,845,739)       $(5,053,029)

     DIVIDENDS                                           -           (424,815)

      SHAREHOLDERS                             $(3,845,739)       $(5,477,844)

     NET LOSS PER COMMON SHARE (BASIC)              $(0.03)            $(0.05)

     NET LOSS PER COMMON SHARE (DILUTED)            $(0.03)            $(0.05)

      OUTSTANDING                              123,444,839        116,008,631

SOURCE CEL-SCI Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. CEL-SCI Announces Exclusive Licensing Agreement for Cancer Drug Multikine(R) for Republic of South Africa
2. CEL-SCI Launches Study to Determine Long Lasting Beneficial Effects of its Rheumatoid Arthritis Vaccine
3. CEL-SCI Presents Favorable Data for Leaps Vaccine Technology at Prestigious Immunology Conference
4. CEL-SCI Corporation Reports Second Quarter 2008 Financial Results
5. CEL-SCI CORPORATION Announces Results of 2008 Annual Meeting of Shareholders and Provides Update on Ground-breaking Activities Regarding Construction of Manufacturing Facility for Pivotal Phase III Cancer Trial
6. CEL-SCI Corporation Releases Letter to Shareholders
7. CEL-SCI Corporation Announces Adoption of Shareholder Rights Plan
8. Comprehensive Review of Cancer Immnunotherapies Published By CEL-SCI
9. Alpine Biomed Corporation to Integrate Bravo pH Monitoring With GastroTrac Software to Enhance Gastrodiagnostic Testing Capabilities
10. Kinovate Life Sciences, Inc. and Nitto Denko Corporation Announce Successful Development of NittoPhase™ HL High Loading Solid Support for Oligonucleotide Synthesis
11. Select Medical Corporation Announces Results for First Quarter Ended March 31, 2009
Post Your Comments:
(Date:6/25/2016)... ... 25, 2016 , ... Austin residents seeking Mohs surgery services, can now turn ... to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization ... selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction ...
(Date:6/25/2016)... Beach, CA (PRWEB) , ... June 25, 2016 , ... ... UCLA with Magna Cum Laude and his M.D from the David Geffen School of ... Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at the ...
(Date:6/24/2016)... ... ... A recent article published June 14 on E Online details ... to state that individuals are now more comfortable seeking to undergo not only the ... and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) notes ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
(Date:6/24/2016)... ... ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for ... $12 an hour by 2020 and then adjusting it yearly to increase at the same ... wage, assure the wage floor does not erode again, and make future increases more predictable. ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016  Collagen Matrix, ... design, development and manufacturing of collagen and mineral ... announced today that Bill Messer has ... Marketing to further leverage the growing portfolio of ... devices. Bill joins the Collagen Matrix ...
(Date:6/24/2016)... Va. , June 24, 2016 The ... set of recommendations that would allow biopharmaceutical ... (HCEI) with entities that make formulary and coverage decisions, ... the "value" of new medicines. The recommendations ... does not appear on the drug label, a prohibition ...
(Date:6/24/2016)... 24, 2016   Pulmatrix, Inc ., (NASDAQ: ... inhaled drugs, announced today that it was added to ... its comprehensive set of U.S. and global equity ... an important milestone for Pulmatrix," said Chief Executive Officer ... of our progress in developing drugs for crucial unmet ...
Breaking Medicine Technology: